Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INO?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements to the market, resulting in investor losses when the truth about manufacturing deficiencies for its CELLECTRA device and insufficient evidence for FDA priority review emerged.
- BLA Filing Delay: Inovio is accused of being unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, which further undermines investor confidence in the company's future prospects and contributed to a decline in stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.720
Low
3.00
Averages
7.33
High
13.00
Current: 1.720
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements to the market, resulting in investor losses when the truth about manufacturing deficiencies for its CELLECTRA device and insufficient evidence for FDA priority review emerged.
- BLA Filing Delay: Inovio is accused of being unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, which further undermines investor confidence in the company's future prospects and contributed to a decline in stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 7, 2026, to participate in the class action against Inovio Pharmaceuticals, concerning securities purchased between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 results, projecting a mid-2025 submission for its Biologics License Application (BLA) due to manufacturing issues, causing a 3.1% stock drop to $8.44 on August 9, 2024, resulting in investor losses.
- FDA Review Update: On December 29, 2025, Inovio announced that the FDA accepted its INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a 24.45% decline in stock price to $1.73, further harming investors.
- False Statements Allegation: The class action alleges that Inovio made materially false or misleading statements throughout the class period, failing to disclose manufacturing deficiencies and their impact on the INO-3107 application, misleading investors about the company's prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, resulting in understated unrealized losses and misleading investors about the company's net asset value (NAV).
- Oracle's Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy led to massive capital expenditure increases without corresponding revenue growth, raising concerns about debt risks and credit ratings, which could undermine investor confidence.
- Risks for Paysafe and Inovio: Paysafe's lawsuit highlights significant exposure to a single high-risk client, potentially hindering revenue growth, while Inovio's manufacturing deficiencies may prevent timely FDA submissions for critical applications, posing risks of investor losses.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Investor Claim Alert: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who suffered losses exceeding $50,000 between October 10, 2023, and December 26, 2025, indicating potential legal risks for the company.
- Legal Action Deadline: Investors must apply to become lead plaintiffs in a federal securities class action by April 7, 2026, highlighting the urgency of the legal process and its implications for investor rights.
- Direct Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers, which demonstrates the firm's commitment to client support and engagement.
- Industry Context: As a NASDAQ-listed company, Inovio Pharmaceuticals faces legal scrutiny that could impact its stock performance, prompting investors to monitor developments closely to safeguard their interests.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in its CELLECTRA device manufacturing, which diminished the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, adversely affecting investor interests.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully select law firms with proven success in securities class actions to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio executives made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in the CELLECTRA device, which led to delays in the submission of the INO-3107 Biologics License Application (BLA), undermining investor confidence.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share due to the expected delay in BLA submission; on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The lawsuit could result in substantial financial liabilities for Inovio, impacting its future fundraising capabilities and market reputation, while severely damaging investor confidence in its commercial prospects and potentially affecting its competitive position in the biotechnology sector.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements to the market, resulting in investor losses when the truth about manufacturing deficiencies for its CELLECTRA device and insufficient evidence for FDA priority review emerged.
- BLA Filing Delay: Inovio is accused of being unlikely to file the INO-3107 Biologics License Application (BLA) by the second half of 2024, which further undermines investor confidence in the company's future prospects and contributed to a decline in stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits aimed at helping investors recover losses.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by April 7, 2026, to participate in the class action against Inovio Pharmaceuticals, concerning securities purchased between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 results, projecting a mid-2025 submission for its Biologics License Application (BLA) due to manufacturing issues, causing a 3.1% stock drop to $8.44 on August 9, 2024, resulting in investor losses.
- FDA Review Update: On December 29, 2025, Inovio announced that the FDA accepted its INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a 24.45% decline in stock price to $1.73, further harming investors.
- False Statements Allegation: The class action alleges that Inovio made materially false or misleading statements throughout the class period, failing to disclose manufacturing deficiencies and their impact on the INO-3107 application, misleading investors about the company's prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, resulting in understated unrealized losses and misleading investors about the company's net asset value (NAV).
- Oracle's Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy led to massive capital expenditure increases without corresponding revenue growth, raising concerns about debt risks and credit ratings, which could undermine investor confidence.
- Risks for Paysafe and Inovio: Paysafe's lawsuit highlights significant exposure to a single high-risk client, potentially hindering revenue growth, while Inovio's manufacturing deficiencies may prevent timely FDA submissions for critical applications, posing risks of investor losses.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Investor Claim Alert: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who suffered losses exceeding $50,000 between October 10, 2023, and December 26, 2025, indicating potential legal risks for the company.
- Legal Action Deadline: Investors must apply to become lead plaintiffs in a federal securities class action by April 7, 2026, highlighting the urgency of the legal process and its implications for investor rights.
- Direct Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers, which demonstrates the firm's commitment to client support and engagement.
- Industry Context: As a NASDAQ-listed company, Inovio Pharmaceuticals faces legal scrutiny that could impact its stock performance, prompting investors to monitor developments closely to safeguard their interests.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in its CELLECTRA device manufacturing, which diminished the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, adversely affecting investor interests.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully select law firms with proven success in securities class actions to ensure effective legal support in the class action, avoiding firms that merely act as intermediaries.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio executives made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in the CELLECTRA device, which led to delays in the submission of the INO-3107 Biologics License Application (BLA), undermining investor confidence.
- Stock Price Volatility: Following the release of its financial results on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share due to the expected delay in BLA submission; on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated.
- Severe Legal Consequences: The lawsuit could result in substantial financial liabilities for Inovio, impacting its future fundraising capabilities and market reputation, while severely damaging investor confidence in its commercial prospects and potentially affecting its competitive position in the biotechnology sector.
See More
